S&P 500 7,628.29 â–ŧ 57.85 (-0.75%) DOW 52,759.94 â–ŧ 425.96 (-0.80%) NASDAQ 26,096.35 â–ŧ 274.54 (-1.04%) US Markets Closed â€ĸ 04:20 PM ET

TNYA

Tenaya Therapeutics, Inc.

Price Chart

No historical data available

Latest Quote

$0.69

-0.01 (-0.73%)
Current Price
Previous Close $0.70
Open $0.70
Day High $0.70
Day Low $0.69
Volume 1,095,765
Fetched: 2026-08-29T13:10:16
Stock Information
Shares Outstanding 224.23M
Total Debt $3.95M
Cash Equivalents $78.08M
Revenue $1.33M
Net Income $-103.11M
Sector Healthcare
Industry Biotechnology
Market Cap $154.74M
EPS (TTM) $-0.51
Exchange NCM
🌐 Visit Website
Recent Price History
No history data available. Data will be fetched automatically.
About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

📰 Latest News
No news articles available at the moment. Check back later for updates on TNYA.
Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $93,331,000 $115,948,000 $131,193,000 $125,621,000
Other Income Expense $52,000 $82,000 $53,000 $2,000
Other Non Operating Income Expenses $52,000 $82,000 $53,000 $2,000
Net Non Operating Interest Income Expense $2,682,000 $4,737,000 $7,056,000 $1,954,000
Operating Expense $93,331,000 $115,948,000 $131,193,000 $125,621,000
General And Administrative Expense $24,724,000 $29,206,000 $33,155,000 $31,084,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Net Interest Income $2,682,000 $4,737,000 $7,056,000 $1,954,000
Interest Income $2,682,000 $4,737,000 $7,056,000 $1,954,000
Normalized Income $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Net Income From Continuing And Discontinued Operation $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Total Operating Income As Reported $-93,331,000 $-115,948,000 $-131,193,000 $-125,621,000
Net Income Common Stockholders $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Net Income $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Net Income Including Noncontrolling Interests $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Net Income Continuous Operations $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Pretax Income $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Interest Income Non Operating $2,682,000 $4,737,000 $7,056,000 $1,954,000
Operating Income $-93,331,000 $-115,948,000 $-131,193,000 $-125,621,000
Per Share
Diluted EPS $-0.59 $-1.31 $-1.68 $-2.76
Basic EPS $-0.59 $-1.31 $-1.68 $-2.76
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-84,895,000 $-107,480,000 $-122,506,000 $-119,154,000
Reconciled Depreciation $8,436,000 $8,468,000 $8,687,000 $6,467,000
EBITDA (Bullshit earnings) $-84,895,000 $-107,480,000 $-122,506,000 $-119,154,000
EBIT $-93,331,000 $-115,948,000 $-131,193,000 $-125,621,000
Diluted Average Shares $152,971,259 $84,822,468 $73,786,126 $44,823,597
Basic Average Shares $152,971,259 $84,822,468 $73,786,126 $44,823,597
Diluted NI Availto Com Stockholders $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Tax Provision $0 $0 $0 $0
Research And Development $68,607,000 $86,742,000 $98,038,000 $94,537,000
Selling General And Administration $24,724,000 $29,206,000 $33,155,000 $31,084,000
Other Gand A $24,724,000 $29,206,000 $33,155,000 $31,084,000
Fetched: 2026-08-17
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $123,265,000 $92,854,000 $139,424,000 $243,376,000
Total Assets $146,921,000 $119,940,000 $170,515,000 $278,945,000
Total Non Current Assets $41,335,000 $52,565,000 $58,933,000 $85,191,000
Other Non Current Assets $4,246,000 $4,817,000 $5,677,000 $4,793,000
Current Assets $105,586,000 $67,375,000 $111,582,000 $193,754,000
Other Current Assets $1,025,000 $842,000 $1,157,000 $938,000
Prepaid Assets $4,014,000 $5,087,000 $5,783,000 $4,044,000
Cash Cash Equivalents And Short Term Investments $100,547,000 $61,446,000 $104,642,000 $186,527,000
Cash And Cash Equivalents $100,547,000 $4,323,000 $45,681,000 $95,272,000
Investmentin Financial Assets - - $0 $17,703,000
Receivables - - $0 $2,245,000
Taxes Receivable - - $0 $2,245,000
Debt
Total Debt $10,830,000 $13,608,000 $12,424,000 $15,099,000
Long Term Debt And Capital Lease Obligation $7,810,000 $10,830,000 $8,105,000 $11,093,000
Current Debt And Capital Lease Obligation $3,020,000 $2,778,000 $4,319,000 $4,006,000
Liabilities
Total Liabilities Net Minority Interest $23,656,000 $27,086,000 $31,091,000 $35,569,000
Total Non Current Liabilities Net Minority Interest $8,220,000 $11,111,000 $8,358,000 $11,321,000
Other Non Current Liabilities $410,000 $281,000 $253,000 $228,000
Current Liabilities $15,436,000 $15,975,000 $22,733,000 $24,248,000
Other Current Liabilities $176,000 $214,000 $478,000 $545,000
Payables And Accrued Expenses $6,227,000 $7,388,000 $9,236,000 $13,274,000
Payables $3,858,000 $5,510,000 $5,910,000 $9,578,000
Total Tax Payable $277,000 $348,000 $280,000 -
Accounts Payable $3,581,000 $5,162,000 $5,630,000 $9,578,000
Non Current Deferred Liabilities - - - -
Current Deferred Liabilities - - - -
Equity
Common Stock Equity $123,265,000 $92,854,000 $139,424,000 $243,376,000
Total Equity Gross Minority Interest $123,265,000 $92,854,000 $139,424,000 $243,376,000
Stockholders Equity $123,265,000 $92,854,000 $139,424,000 $243,376,000
Gains Losses Not Affecting Retained Earnings $0 $28,000 $-106,000 $-378,000
Retained Earnings $-605,008,000 $-514,411,000 $-403,282,000 $-279,198,000
Other Equity Adjustments - $28,000 $-106,000 $-378,000
Preferred Securities Outside Stock Equity - - - -
Other
Ordinary Shares Number $216,760,283 $86,542,340 $68,330,342 $66,857,113
Share Issued $216,760,283 $86,542,340 $68,330,342 $66,857,113
Tangible Book Value $123,265,000 $92,854,000 $139,424,000 $243,376,000
Invested Capital $123,265,000 $92,854,000 $139,424,000 $243,376,000
Working Capital $90,150,000 $51,400,000 $88,849,000 $169,506,000
Capital Lease Obligations $10,830,000 $13,608,000 $12,424,000 $15,099,000
Total Capitalization $123,265,000 $92,854,000 $139,424,000 $243,376,000
Additional Paid In Capital $728,252,000 $607,229,000 $542,805,000 $522,945,000
Capital Stock $21,000 $8,000 $7,000 $7,000
Common Stock $21,000 $8,000 $7,000 $7,000
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $7,810,000 $10,830,000 $8,105,000 $11,093,000
Current Capital Lease Obligation $3,020,000 $2,778,000 $4,319,000 $4,006,000
Pensionand Other Post Retirement Benefit Plans Current $6,013,000 $5,595,000 $8,700,000 $6,423,000
Current Accrued Expenses $2,369,000 $1,878,000 $3,326,000 $3,696,000
Net PPE $37,089,000 $47,748,000 $53,256,000 $62,695,000
Accumulated Depreciation $-39,933,000 $-32,290,000 $-24,340,000 $-15,676,000
Gross PPE $77,022,000 $80,038,000 $77,596,000 $78,371,000
Leases $26,244,000 $26,159,000 $25,608,000 $23,605,000
Construction In Progress $67,000 $1,915,000 $1,730,000 $3,128,000
Other Properties $28,431,000 $31,660,000 $29,952,000 $32,200,000
Machinery Furniture Equipment $22,280,000 $20,304,000 $20,306,000 $19,438,000
Properties $0 $0 $0 $0
Other Short Term Investments $0 $57,123,000 $58,961,000 $91,255,000
Treasury Shares Number - - $0 -
Investments And Advances - - $0 $17,703,000
Available For Sale Securities - - - $17,703,000
Fetched: 2026-08-17
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-68,882,000 $-91,526,000 $-103,311,000 $-125,054,000
Operating Activities
Operating Cash Flow $-68,264,000 $-90,501,000 $-102,072,000 $-104,424,000
Cash Flow From Continuing Operating Activities $-68,264,000 $-90,501,000 $-102,072,000 $-104,424,000
Operating Gains Losses - - - -
Investing Activities
Capital Expenditure $-618,000 $-1,025,000 $-1,239,000 $-20,630,000
Investing Cash Flow $56,083,000 $1,131,000 $48,715,000 $83,652,000
Cash Flow From Continuing Investing Activities $56,083,000 $1,131,000 $48,715,000 $83,652,000
Net Other Investing Changes - $17,000 $-25,000 $8,000
Financing Activities
Issuance Of Capital Stock $105,977,000 $46,762,000 $3,868,000 $77,387,000
Financing Cash Flow $108,405,000 $47,749,000 $4,049,000 $77,767,000
Cash Flow From Continuing Financing Activities $108,405,000 $47,749,000 $4,049,000 $77,767,000
Net Common Stock Issuance $105,977,000 $46,762,000 $3,868,000 $77,387,000
Common Stock Issuance $105,977,000 $46,762,000 $3,868,000 $77,387,000
Net Other Financing Charges - - $-501,000 -
Repurchase Of Capital Stock - - - $0
Net Preferred Stock Issuance - - - $0
Preferred Stock Issuance - - - $0
Other
End Cash Position $100,966,000 $4,742,000 $46,363,000 $95,671,000
Beginning Cash Position $4,742,000 $46,363,000 $95,671,000 $38,676,000
Changes In Cash $96,224,000 $-41,621,000 $-49,308,000 $56,995,000
Proceeds From Stock Option Exercised $2,428,000 $987,000 $682,000 $380,000
Net Investment Purchase And Sale $56,701,000 $2,139,000 $49,979,000 $104,274,000
Sale Of Investment $56,701,000 $89,208,000 $106,623,000 $244,750,000
Purchase Of Investment $0 $-87,069,000 $-56,644,000 $-140,476,000
Net PPE Purchase And Sale $-618,000 $-1,025,000 $-1,239,000 $-20,630,000
Purchase Of PPE $-618,000 $-1,025,000 $-1,239,000 $-20,630,000
Change In Working Capital $-2,456,000 $-7,931,000 $-5,648,000 $-849,000
Change In Other Current Liabilities $-2,676,000 $-4,118,000 $-4,122,000 $-3,108,000
Change In Other Current Assets $571,000 $656,000 $-601,000 $-815,000
Change In Payables And Accrued Expense $-898,000 $-5,326,000 $-1,026,000 $6,008,000
Change In Accrued Expense $532,000 $-4,745,000 $2,256,000 $4,348,000
Change In Payable $-1,430,000 $-581,000 $-3,282,000 $1,660,000
Change In Account Payable $-1,430,000 $-581,000 $-3,282,000 $1,660,000
Change In Prepaid Assets $547,000 $857,000 $101,000 $-2,934,000
Other Non Cash Items $2,896,000 $3,774,000 $3,349,000 $2,463,000
Stock Based Compensation $13,046,000 $16,501,000 $15,309,000 $11,467,000
Amortization Of Securities $411,000 $-184,000 $315,000 $-307,000
Depreciation Amortization Depletion $8,436,000 $8,468,000 $8,687,000 $6,467,000
Depreciation And Amortization $8,436,000 $8,468,000 $8,687,000 $6,467,000
Net Income From Continuing Operations $-90,597,000 $-111,129,000 $-124,084,000 $-123,665,000
Depreciation - $8,468,000 $8,687,000 $6,467,000
Common Stock Payments - - - $0
Gain Loss On Sale Of PPE - - - -
Fetched: 2026-08-17